ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement

ERS Genomics Limited (‘ERS’), the CRISPR licensing Company, and Université de Montréal (‘UdeM’), a leading Canadian research institution renowned for scientific innovation and technology transfer, today announced a non-exclusive CRISPR/Cas9 license agreement.

The agreement grants the university access to ERS’ CRISPR/Cas9 patent portfolio – including enabling the launch of two CRISPR/Cas9 screening facility platforms at UdeM's Institute for Research in Immunology and Cancer.

Lynda Adam, PhD, Director of Technology Transfer, Innovation and Partnerships, Université de Montréal, said: “With the acquisition of this license, we have launched platform services that will broaden access to genome-wide CRISPR screening and data to the research community. Furthermore, this licence enables UdeM researchers to carry out project collaborations and partnerships using CRISPR technology under certain conditions.”

John E. Milad, CEO, ERS Genomics, commented: “Université de Montréal has a reputation for making outstanding contributions to scientific innovation. Providing this license and access to the CVC patent portfolio has enabled the launch of screening platforms which will play a role in uncovering new therapeutic targets and ultimately improve healthcare outcomes. We look forward to seeing the transformative impact of their work on global medical challenges.”

CRISPR gene editing is a genetic engineering technique in molecular biology by which the genomes of living organisms may be modified. It is based on a simplified version of the bacterial CRISPR-Cas9 antiviral defence system. The development of the technique earned biochemists Emmanuelle Charpentier (one of the founders of ERS Genomics) and Jennifer Doudna the Nobel Prize in Chemistry in 2020.

ERS Genomics provides licensing to CRISPR/Cas9 technology for companies interested in pursuing its use in their commercial programs. Comprising 100+ patents globally, ERS’ portfolio encompasses CRISPR/Cas9 usage in all cells, including bacteria, archaea, yeasts, and algae. ERS Genomics licenses these patents via its direct license from Emmanuelle Charpentier and now has nearly 150 licenses in place worldwide.

Financial details of the agreement are not disclosed.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ERS Genomics. (2024, October 01). ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement. News-Medical. Retrieved on October 08, 2024 from https://www.news-medical.net/news/20241001/ERS-Genomics-and-Universite-de-Montreal-sign-CRISPRCas9-license-agreement.aspx.

  • MLA

    ERS Genomics. "ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement". News-Medical. 08 October 2024. <https://www.news-medical.net/news/20241001/ERS-Genomics-and-Universite-de-Montreal-sign-CRISPRCas9-license-agreement.aspx>.

  • Chicago

    ERS Genomics. "ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement". News-Medical. https://www.news-medical.net/news/20241001/ERS-Genomics-and-Universite-de-Montreal-sign-CRISPRCas9-license-agreement.aspx. (accessed October 08, 2024).

  • Harvard

    ERS Genomics. 2024. ERS Genomics and Université de Montréal sign CRISPR/Cas9 license agreement. News-Medical, viewed 08 October 2024, https://www.news-medical.net/news/20241001/ERS-Genomics-and-Universite-de-Montreal-sign-CRISPRCas9-license-agreement.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Key Charpentier/Doudna CRISPR patent upheld by China National Intellectual Property Administration